药易购“95后”董事拟豪掷1.2亿元 从实控人手中拿下公司超5%股份

Core Viewpoint - The recent investment by the newly appointed director Gan Meng in Yaoyigou indicates a strategic move to enhance the company's talent pool and diversify its operations despite the company's current financial struggles [1][2][3]. Group 1: Investment Details - Gan Meng, who joined Yaoyigou just over three months ago, plans to invest 120 million yuan to acquire 5.23% of the company's shares at a price of 24 yuan per share [1]. - Following this transaction, the controlling shareholder Li Yanfei and his associates will see their shareholding decrease to 38.75% [1]. - Gan Meng's investment will be funded entirely from his own or self-raised funds, and he did not hold any shares prior to this agreement [1]. Group 2: Company Performance - Yaoyigou reported a net profit loss of 742,100 yuan for the third quarter of 2025, marking a shift from profit to loss [3]. - For the first three quarters of the year, the company experienced a total net profit loss of 8.36 million yuan, with a significant decline in cash flow, showing a negative net cash flow of 11.4 million yuan [3]. - The company's performance has deteriorated after a significant profit increase of 556.48% in 2022, with 2023 showing a clear downturn [3]. Group 3: Strategic Implications - Internal sources suggest that Gan Meng's entry as a shareholder is aimed at bringing in talent and supporting the company's diversified development strategy [2]. - The company is focusing on building a technology-driven health ecosystem, which necessitates the introduction of more specialized talent to enhance its operational capabilities [2]. - The transition of leadership from Li Yanfei, who stepped down as chairman in July, is seen as a move that will not affect his control over the company, indicating ongoing confidence in the company's future [4].